A Phase 2, Multicenter, Randomized, Double-blind Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Erlotinib (Primary) ; Ficlatuzumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms FOCAL
- Sponsors AVEO Oncology
- 08 Jun 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Sep 2017.
- 08 Jun 2017 Status changed from active, no longer recruiting to discontinued.
- 28 Sep 2016 Status changed from recruiting to active, no longer recruiting.